Vital Signs - Are Biosimilars On the U.S. Horizon?
Vital Signs - Are Biosimilars On the U.S. Horizon?
RELEASE DATE
23-Jun-2008
23-Jun-2008
REGION
North America
North America
Research Code: 9561-00-66-00-00
SKU: HC00533-NA-MR_04005
$1,500.00
Special Price $1,125.00 save 25 %
In stock
SKU
HC00533-NA-MR_04005
Description
This issue of Vital Signs, released on June 23, 2008, provides an strategic overview of the issues surrounding generic biotechnology drugs and their approval pathway in the U.S. Additionally, a company spotlight is provided for InNexus Biotechnology, a biotechnology drug development company focused on next-generation monoclonal antibodies. Reimbursement and regulatory news from the FDA is also provided for the week of June 9, 2008.
Table of Contents
This week's issue:
Related Research
This issue of Vital Signs, released on June 23, 2008, provides an strategic overview of the issues surrounding generic biotechnology drugs and their approval pathway in the U.S. Additionally, a company spotlight is provided for InNexus Biotechnology, a biotechnology drug development company focused on next-generation monoclonal antibodies. Reimbursement and regulatory news from the FDA is also provided for the week of June 9, 2008.
No Index | Yes |
---|---|
Podcast | No |
Industries | Healthcare |
WIP Number | 9561-00-66-00-00 |
Is Prebook | No |